Programme
Precision Oncology • Molecular Tumour Board • Modern Radiotherapy • Clinical Grand Round
| Time | SCIENTIFIC PROGRAMME |
|---|---|
|
12:30–14:00
|
Registration & Welcome Coffee
|
|
14:00 -14:30
|
Opening Ceremony — Welcome addresses by MARO, institutional and international representatives
|
|
14:30 -15:00
|
Opening Plenary: Multidisciplinary Precision Oncology — Translating Evidence into Better Clinical Outcomes
|
|
15:00 – 16:30 |
SESSION 1 • PRECISION ONCOLOGY IN DAILY CLINICAL PRACTICE Session chairs: Pathologist • Molecular biologist • Medical oncologist • Radiation oncologist (TBC) |
|
15:00 – 15:20 |
The modern diagnostic pathway: integrating morphology, immunohistochemistry, imaging and
molecular classification |
|
15:20 – 15:40 |
Choosing the right biomarker test: tissue, NGS and circulating tumour DNA in clinical practice |
|
15:40 – 16:00 |
From molecular alteration to treatment: evidence levels, ESCAT actionability and clinical prioritisation |
|
16:00 – 16:30 |
Live Molecular Tumour Board: standard of care, clinical trial or off-label treatment? |
|
16:30 – 17:00 |
Coffee Break & Poster Viewing |
|
17:00 – 18:30 |
SESSION 2 • MODERN RADIOTHERAPY: PRECISION, INTEGRATION
AND CLINICAL IMPACT Session chairs: Radiation oncologist • Medical physicist • Medical oncologist • Radiologist (TBC) |
|
17:00 – 17:20 |
Precision radiotherapy today: IGRT, VMAT, motion management and online adaptive treatment |
|
17:20 – 17:40 |
SRS and SBRT across the disease course: early-stage, oligometastatic and oligoprogressive cancer |
|
17:40 – 18:00 |
Combining radiotherapy with immunotherapy and targeted agents: efficacy, sequencing and safety |
|
18:00 – 18:30 |
Radiotherapy clinical case board: target definition, dose, fractionation and toxicity trade-offs |
|
18:30 – 19:15 |
MULTIDISCIPLINARY CLINICAL GRAND ROUND • THE LOCALLY
ADVANCED PATIENT Panel: Surgeon • Pathologist • Radiologist • Medical oncologist • Radiation oncologist (TBC) |
|
18:30 – 19:15 |
One complex case, five perspectives: diagnosis, resectability, systemic therapy, radiotherapy and treatment sequencing |
|
19:30 |
Welcome reception |
Clinical MDT Tracks • Breast • Lung • Melanoma & Skin Cancers • Neuro-Oncology
| Time | SCIENTIFIC PROGRAMME |
|---|---|
|
08:30–10:30
|
SESSION 3 • BREAST CANCER: FROM MOLECULAR SUBTYPE TO AN
INTEGRATED TREATMENT PLAN Session chairs: Breast surgeon • Pathologist • Radiologist • Medical oncologist • Radiation oncologist (TBC) |
|
08:30 -08:50
|
Clinical work-up and risk stratification: imaging, pathology, biomarkers and genomic signatures |
|
08:50 – 09:10 |
Neoadjuvant and post-neoadjuvant strategies in HER2-positive and triple-negative breast cancer |
|
09:10 – 09:30 |
HR-positive/HER2-negative disease: precision escalation and de-escalation in early and advanced settings |
|
09:30 – 09:50 |
Modern breast radiotherapy: partial-breast treatment, hypofractionation, boost and regional nodal irradiation |
|
09:50 – 10:10 |
Surgical decision-making after systemic therapy: breast and axillary management |
|
10:10- 10:30 |
Breast MDT case: balancing local control, systemic risk and patient preference |
|
10:30 – 11:00 |
Coffee Break & Poster Viewing |
|
11:00 – 13:00 |
SESSION 4 • LUNG CANCER: STAGE-ADAPTED MULTIDISCIPLINARY
AND PRECISION TREATMENT Session chairs: Radiation oncologist • Medical physicist • Medical oncologist • Radiologist (TBC) |
|
11:00 – 11:20 |
From nodule to molecular profile: optimal tissue acquisition, staging and biomarker testing |
|
11:20 – 11:40 |
Early-stage NSCLC: surgery, sublobar resection or stereotactic body radiotherapy? |
|
11:40 – 12:00 |
Resectable NSCLC: perioperative immunotherapy and targeted therapy in multidisciplinary practice |
|
12:00 – 12:20 |
Unresectable stage III NSCLC: modern chemoradiotherapy, planning quality and consolidation |
|
12:20 – 12:40 |
Metastatic NSCLC: precision systemic therapy and local treatment for
oligometastatic/oligoprogressive disease |
|
12:40 – 13:00 |
Thoracic MDT case: staging uncertainty, operability and sequencing of systemic and local therapy |
|
13:00 – 14:00 |
Lunch & Poster Viewing |
|
14:00 – 15:40 |
SESSION 5 • MELANOMA AND SKIN CANCERS: FROM CURATIVE
SURGERY TO COMPLEX SYSTEMIC CARE Session chairs: Dermatologist • Pathologist • Surgeon • Medical oncologist • Radiation oncologist (TBC)) |
|
14:00 – 14:20 |
Pathology and imaging for clinical decisions: staging, margins, nodal assessment and predictive biomarkers |
|
14:20 – 14:40 |
Neoadjuvant and adjuvant therapy in high-risk melanoma |
|
14:40 – 15:00 |
Advanced melanoma: sequencing immunotherapy and targeted therapy |
|
15:00 – 15:20 |
Radiotherapy in melanoma and complex skin cancer: adjuvant treatment, palliation and stereotactic approaches |
|
15:20 – 15:40 |
Skin cancer MDT case: organ preservation, local control and systemic options |
|
15:40 – 16:10 |
Coffee Break |
|
16:10 – 17:50 |
SESSION 6• NEURO-ONCOLOGY: INTEGRATED CARE FOR PRIMARY
AND METASTATIC BRAIN TUMOURS Session chairs: Session chairs: Neurosurgeon • Neuropathologist • Neuroradiologist • Medical oncologist • Radiation oncologist (TBC) |
|
16:10 – 16:30 |
Integrated neuropathological diagnosis: translating WHO molecular classification into practice |
|
16:30 – 16:50 |
Newly diagnosed and recurrent diffuse gliomas: molecularly informed systemic treatment |
|
16:50 – 17:10 |
Modern radiotherapy for CNS tumours: target definition, precision planning, re-irradiation and toxicity reduction |
|
17:10 – 17:30 |
Brain metastases: surgery, SRS/SRT and systemic therapy in a rapidly changing landscape |
|
17:30 – 17:50 |
Neuro-oncology MDT case: integrating imaging, pathology, function and prognosis |
|
17:50 – 18:30 |
Young Investigators’ Forum & Moderated Poster Walk |
|
20:00 |
Congress DInner |
Clinical MDT Tracks • Gynaecological • Colorectal • Gastric & Upper GI Cancers
| Time | SCIENTIFIC PROGRAMME |
|---|---|
|
08:30–10:30
|
SESSION 7 • GYNAECOLOGICAL CANCERS: PATHOLOGY-DRIVEN,
MULTIMODAL, PERSONALISED Session chairs: Gynaecologic oncologist • Pathologist • Medical oncologist • Radiation oncologist (TBC) |
|
08:30 -08:50
|
Molecular classification in endometrial and ovarian cancer: practical pathology for treatment planning |
|
08:50 – 09:10 |
Locally advanced cervical cancer: imaging, concurrent systemic therapy, precision EBRT and image-
guided brachytherapy |
|
09:10 – 09:30 |
Endometrial cancer: risk-adapted adjuvant treatment and systemic options in advanced disease |
|
09:30 – 09:50 |
Ovarian cancer: surgery, maintenance strategies and biomarker-guided treatment |
|
09:50 – 10:10 |
Recurrent gynaecological cancers: immunotherapy, targeted treatment, salvage surgery and re-irradiation |
|
10:10- 10:30 |
Gynaecological MDT case: integrating pathology, operability, radiotherapy and systemic therapy |
|
10:30 – 11:00 |
Coffee Break & Poster Viewing |
|
11:00 – 12:40 |
SESSION 8 • COLORECTAL CANCER: ORGAN PRESERVATION,
PRECISION AND OLIGOMETASTATIC CARE Session chairs: Colorectal surgeon • Gastroenterologist • Pathologist • Medical oncologist • Radiation oncologist (TBC)) |
|
11:00 – 11:20 |
Rectal cancer after total neoadjuvant therapy: selection, sequencing and response assessment |
|
11:20 – 11:40 |
Watch-and-wait and organ preservation: evidence, surveillance and shared decision-making |
|
11:40 – 12:00 |
Molecularly defined metastatic colorectal cancer: treatment pathways and resistance |
|
12:00 – 12:20 |
Liver-limited and oligometastatic disease: surgery, ablation and stereotactic radiotherapy |
|
12:20 – 12:40 |
Colorectal MDT case: sequencing local and systemic treatment across disciplines |
|
12:40 – 13:40 |
Lunch & Poster Viewing |
|
13:40 – 15:20 |
SESSION 9 • GASTRIC AND UPPER GI CANCERS: BIOMARKERS AND
MULTIMODAL STRATEGIES Session chairs: Upper GI surgeon • Gastroenterologist • Pathologist • Medical oncologist • Radiation oncologist (TBC) |
|
13:40 – 14:00 |
Essential pathology and biomarkers in gastric/GEJ cancer: HER2, PD-L1, MSI/MMR and CLDN18.2 |
|
14:00 – 14:20 |
Perioperative therapy for resectable gastric and gastro-oesophageal junction cancer |
|
14:20 – 14:40 |
Advanced gastric cancer: biomarker-directed first-line and later-line strategies |
|
14:40 – 15:00 |
Oesophageal and GEJ cancer: definitive chemoradiotherapy, neoadjuvant therapy and surgical
selection |
|
15:00 – 15:20 |
Upper GI MDT case: from endoscopy and pathology to a coordinated treatment plan |
|
15:20 – 15:50 |
Coffee Break |
|
15:50 – 16:50 |
FINAL MULTIDISCIPLINARY CLINICAL GRAND ROUND • THREE
DIFFICULT CASES Panel: Pathologist • Radiologist • Surgeon • Medical oncologist • Radiation oncologist (TBC) |
|
15:50 – 16:50 |
Case-based decisions in precision oncology: interpreting biomarkers, defining treatment intent and
sequencing surgery, systemic therapy and radiotherapy |
|
16:50 – 17:20 |
Awards, Congress Conclusions & Closing Ceremony |